Summary of Product Characteristics (SmPC) - Zipzoc 20% Impregnated dressing
1 NAME OF THE MEDICINAL PRODUCT
Zipzoc 20%, impregnated dressing
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
20% Zinc Oxide
Each stocking (80cm x 7cm) contains about 41.5g of ointment
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Impregnated dressing
Zipzoc is a sterile rayon stocking impregnated with an ointment containing Zinc Oxide
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
To be used as an aid in the treatment of chronic venous leg ulcers. Where chronic venous insufficiency exists, the stocking can be used as a primary contact layer under compression bandaging or hosiery.
4.2 Posology and method of administration
Posology
Zipzoc should be applied to cover the lower leg from the base of the toes to below the knee. All folds should be smoothed out. In the case of excessive calf size care should be taken to apply the stocking without constricting the lower leg. A suitable outer bandage or dressing should be used to prevent soiling of clothes. If chronic venous insufficiency exists, Zipzoc can be used as a primary contact layer under suitable compression bandaging.
The duration and frequency of application will depend on the clinical circumstances, but Zipzoc must be changed no less frequently than weekly.
Method of administration
For cutaneous use.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 Arterial leg ulcers.
4.4 Special warnings and precautions for use
If outer bandage is inappropriate or the stocking is not changed with sufficient frequency it can cause the stocking to dry out.
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Fertility, Pregnancy and lactation
There is no evidence to suggest Zipzoc should not be used during pregnancy or lactation.
4.7 Effects on ability to drive and use machines
It is unlikely to have an effect.
4.8 Undesirable effects
General disorders and administration site conditions
Very rare: Application site pain
Very rare: Oedema
Skin and subcutaneous tissue disorders
Very rare: Application site folliculitis
Very rare: Erythema.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
4.9 Overdose
None known
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
ATC-code: D09A B01
The stocking consists of a tubular rayon gauze impregnated with zinc oxide Ph. Eur. 20% in an ointment base. Zinc oxide has a soothing and protective effect. Zipzoc has no effect on the underlying condition of chronic venous leg ulcers but can be used under appropriate compression bandaging where chronic venous insufficiency is the problem.
5.2 Pharmacokinetic properties
Not applicable.
5.3 Preclinical safety data
Nothing relevant to add to the prescribing information.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Ointment base consists of:
Liquid Paraffin
White Soft Paraffin
6.2 Incompatibilities
Not applicable
6.3 Shelf life
3 years.
6.4 Special precautions for storage
Do not store above 30ºC.
6.5 Nature and contents of container
Polyethylene aluminium foil laminated pouches, each pouch containing a single stocking. The outer carton will contain 1, 4 or 10 pouches. Each pouch contains a tubular rayon gauze stocking impregnated with about 41.5g of ointment.
6.6 Special precautions for disposal
No special requirements for disposal.
7 MARKETING AUTHORISATION HOLDER
Evolan Pharma AB
Box 120
182 12 Danderyd
8 MARKETING AUTHORISATION NUMBER(S)
PL 44616/0002
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
01/10/2006
10 DATE OF REVISION OF THE TEXT
11/08/2020